Daniel J Lips

Daniel J Lips

Auto-generated profile, based on publicly available information

Daniel J Lips

Department of Surgery, Jeroen Bosch Hospital, Nieuwstraat 34, 5211 NL 's-Hertogenbosch, the Netherlands

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2011 in BMC Surgery
Verified
Journal Article
Open access
PDF file
DLDaniel J Lips
Daniel J Lips
BKBoukje Koebrugge
Boukje Koebrugge
GLGerrit Jan Liefers
Gerrit Jan Liefers
JLJohannes C van de Linden
Johannes C van de Linden
VSVincentius Smit
Vincentius Smit
KBKoop Bosscha
Koop Bosscha
The presence of lymph node metastases remains the most reliable prognostic predictor and the gold indicator for adjuvant treatment in colon cancer (CC). In spite of a potentially curative resection, 20 to 30% of CC patients testing negative for lymph node metastases (i.e. pN0) will subsequently develop locoregional and/or systemic metastases within 5 years. The presence of occult nodal isolated tumor cells (ITCs) and/or micrometastases (MMs) at the time of resection predisposes CC patients to high risk for disease recurrence. These pN0micro+ patients harbouring occult micrometastases may benefit from adjuvant treatment. The purpose of the present study is to delineate the subset of pN0 patients with micrometastases (pN0micro+) and evaluate the benefits from adjuvant chemotherapy in pN0micro+ CC patients. EnRoute+ is an open label, multicenter, randomized controlled clinical trial. All CC patients (age above 18 years) without synchronous locoregional lymph node and/or systemic metastases (clinical stage I-II disease) and operated upon with curative intent are eligible for inclusion. All resected specimens of patients are subject to an ex vivo sentinel lymph node mapping procedure (SLNM) following curative resection. The investigation for micrometastases in pN0 patients is done by extended serial sectioning and immunohistochemistry for pan-cytokeratin in sentinel lymph nodes which are tumour negative upon standard pathological examination. Patients with ITC/MM-positive sentinel lymph nodes (pN0micro+) are randomized for adjuvant chemotherapy following the CAPOX treatment scheme or observation. The primary endpoint is 3-year disease free survival (DFS). The EnRoute+ study is designed to improve prognosis in high-risk stage I/II pN0 micro+ CC patients by reducing disease recurrence by adjuvant chemotherapy. ClinicalTrials.gov: NCT01097265

30 September 2011 in European Journal of Cancer
Verified
Journal Article
Closed access
BKB. Koebrugge
B. Koebrugge
DLD.J. Lips
D.J. Lips
FVF.J. Vogelaar
F.J. Vogelaar
JPJ.F. Pruijt
J.F. Pruijt
JLJ.C. van der Linden
J.C. van der Linden
KBK. Bosscha
K. Bosscha

20 January 2011 in British Journal of Surgery
Verified
Journal Article
Open access
PDF file
DLD J Lips
D J Lips
BKB Koebrugge
B Koebrugge
CVC van de Velde
C van de Velde
KBK Bosscha
K Bosscha
Sir

30 September 2011 in European Journal of Cancer
Verified
Journal Article
Closed access
PDF file
BKB. Koebruqqe
B. Koebruqqe
LSL.N. van Steenbergen
L.N. van Steenbergen
DLD.J. Lips
D.J. Lips
VLV.E.P.R. Lemmens
V.E.P.R. Lemmens
JLJ.C. van der Linden
J.C. van der Linden
KBK. Bosscha
K. Bosscha

30 September 2011 in European Journal of Cancer
Verified
Journal Article
Closed access
PDF file
BKB. Koebruqqe
B. Koebruqqe
LSL.N. van Steenbergen
L.N. van Steenbergen
DLD.J. Lips
D.J. Lips
VLV.E.P.R. Lemmens
V.E.P.R. Lemmens
JLJ.C. van der Linden
J.C. van der Linden
KBK. Bosscha
K. Bosscha

30 September 2011 in European Journal of Cancer
Verified
Journal Article
Closed access
ADA.E. Dassen
A.E. Dassen
DLD.J. Lips
D.J. Lips
AWA.A.M. van der Wulff
A.A.M. van der Wulff
JPJ.F.M. Pruijt
J.F.M. Pruijt
GCG.J. Creemers
G.J. Creemers
KBK. Bosscha
K. Bosscha